Evaluation of dose-efficacy of sorafenib and effect of transarterial chemoembolization in hepatocellular carcinoma patients: a retrospective study
Authors:
Open Access
- 27 April 2016
- journal article
- research article
- Published by Springer Nature in BMC Gastroenterology
- Vol. 16 (1) , 50
Abstract
No abstract availableKeywords
This publication has 25 references indexed in Scilit:
- Management of Hepatocellular Carcinoma: An Update ΔσHepatology, 2011
- Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinomaHepatology International, 2010
- Current Strategy for Staging and Treatment: The BCLC Update and Future ProspectsSeminars in Liver Disease, 2010
- Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trialThe Lancet Oncology, 2009
- Sorafenib in Advanced Hepatocellular CarcinomaNew England Journal of Medicine, 2008
- Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft modelsCancer Chemotherapy and Pharmacology, 2006
- Angiogenesis and hepatocellular carcinomaJournal of Hepatology, 2004
- BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and AngiogenesisCancer Research, 2004
- Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomyJournal of Hepatology, 2003
- Activation of mitogen-activated protein kinases/extracellular signal-regulated kinases in human hepatocellular carcinomaHepatology, 1998